About this trial
The purpose of the study is to check how safe and well-tolerated \[18F\]LY4214835 injection is in healthy participants and participants with cancer. The study drug will be administered intravenously (IV) (into a vein). Participation in the study will last approximately 35 days.
Eligibility criteria
This trial accepts healthy volunteersQualifiers
Cohort 1
Have a radiologically, cytologically, or histologically confirmed diagnosis of cancer
Are treatment-naïve to a systemic cancer therapy, OR have a documented disease progression on standard-of-care treatment (for example, failure of chemotherapy, targeted therapy or immunotherapy)
Have at least 1 imageable tumor that is 15 millimeter (mm) or larger in the longest diameter
Disqualifiers
Are pregnant or intend to become pregnant during their participation in the study
Are breastfeeding or intending to breastfeed during their participation in the study
Have a history of risk factors for Torsades de Pointes (for example, heart failure, hypokalemia, family history of Long QT Syndrome)
Are actively receiving cancer therapy or are in between cycles of treatment
Trial design
Single group
Treatments tested in this trial
LY4214835
DrugAdministered IV
Treatment groups
Trial outcomes
Primary outcomes
Number of Incidence of Adverse Events (AEs)
Evaluation of AEs regardless of causality, will be reported in the Reported AEs module
Number of Radiation Absorbed Dose Estimates in Body Organs to Obtain Whole-body Effective Dose
Determination of the radiation dosimetry absorbed dose in body organs and whole-body effective dose
Secondary outcomes
Number of Uptake of [18F]LY4214835 in Tumor Foci and Other Organs
Evaluation of the uptake of \[18F\]LY4214835 in tumor foci and other organs
Sponsors and contacts
Click on the lead sponsor to view all of their trials.